Early diagnosis of melanoma: what do we know?

Malignant melanoma is a potentially lethal disease with an excellent prognosis if detected early. In this paper, we review the pathophysiology, clinical presentation, epidemiology, and risk factors for melanoma. We also examine clinical models for predicting risk and survival, and critically appraise data on the effectiveness of screening for melanoma. K EY WORDS: Melanoma, diagnosis - Melanoma, pathology - Skin neoplasms.

[1]  B. Vrouenraets,et al.  Isolated limb perfusion for melanoma. , 2008, Surgical oncology clinics of North America.

[2]  R. Scolyer,et al.  Subungual Melanoma: A Study of 124 Cases Highlighting Features of Early Lesions, Potential Pitfalls in Diagnosis, and Guidelines for Histologic Reporting , 2007, The American journal of surgical pathology.

[3]  P. LoRusso,et al.  Clinical experience of MEK inhibitors in cancer therapy. , 2007, Biochimica et biophysica acta.

[4]  K. Griffith,et al.  Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. , 2007, Surgery.

[5]  Lynn M. Williams,et al.  IL-10 Induces IL-10 in Primary Human Monocyte-Derived Macrophages via the Transcription Factor Stat31 , 2007, The Journal of Immunology.

[6]  D. Elder,et al.  Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Halpern,et al.  Early melanoma diagnosis: a success story that leaves room for improvement , 2007, Current opinion in oncology.

[8]  R. Scolyer,et al.  Diagnosis of metastatic melanoma by fine-needle biopsy: analysis of 2,204 cases. , 2007, American journal of clinical pathology.

[9]  R. Marais,et al.  Melanoma biology and new targeted therapy , 2007, Nature.

[10]  H. Vogel,et al.  CHD5 Is a Tumor Suppressor at Human 1p36 , 2007, Cell.

[11]  C. Schulman,et al.  Use of statins and outcome of BCG treatment for bladder cancer. , 2006, The New England journal of medicine.

[12]  Jane Goodall,et al.  Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. , 2006, Genes & development.

[13]  M. Duvic,et al.  Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma , 2006, British Journal of Cancer.

[14]  D. Elder,et al.  Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma , 2006, Cancer.

[15]  Michael Rytting,et al.  Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. , 2006, Blood.

[16]  U. Rapp,et al.  Raf kinases: Oncogenesis and drug discovery , 2006, International journal of cancer.

[17]  Mark A. Brown,et al.  Epigenetic aberrations and cancer , 2006, Molecular Cancer.

[18]  M. Berwick.  Evaluating early detection in the diagnosis of melanoma. , 2006, Archives of dermatology.

[19]  D. English,et al.  The relationship between melanoma thickness and time to diagnosis in a large population-based study. , 2006, Archives of dermatology.

[20]  Scott R. Freeman,et al.  Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. , 2006, Journal of the National Cancer Institute.

[21]  S. Aamdal,et al.  Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA , 2006, Cancer Gene Therapy.

[22]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[23]  M. Landthaler,et al.  Loss of dipeptidyl peptidase IV immunostaining discriminates malignant melanomas from deep penetrating nevi , 2006, Modern Pathology.

[24]  Michael Detmar,et al.  Tumor and lymph node lymphangiogenesis—impact on cancer metastasis , 2006, Journal of leukocyte biology.

[25]  S. Wilhelm,et al.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.

[26]  R. Elashoff,et al.  Sentinel-node biopsy or nodal observation in melanoma. , 2006, The New England journal of medicine.

[27]  D. Fisher,et al.  Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning , 2006, Nature.

[28]  J. Arlette,et al.  Mohs micrographic surgery in the treatment of lentigo maligna and melanoma , 2006, Journal of surgical oncology.

[29]  D. Pinkel,et al.  Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  N. Ibrahim,et al.  Therapeutic targets in melanoma: MAPKinase pathway , 2006, Current oncology reports.

[31]  L. Old,et al.  Blood Dendritic Cells Generated With Flt3 Ligand and CD40 Ligand Prime CD8+ T Cells Efficiently in Cancer Patients , 2006, Journal of immunotherapy.

[32]  Jeffrey E. Lee,et al.  Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. Fisher,et al.  MITF: master regulator of melanocyte development and melanoma oncogene. , 2006, Trends in molecular medicine.

[34]  Iris Zalaudek,et al.  Why perform dermoscopy? The evidence for its role in the routine management of pigmented skin lesions. , 2006, Archives of dermatology.

[35]  L. Chin,et al.  Malignant melanoma: genetics and therapeutics in the genomic era. , 2006, Genes & development.

[36]  Yunfeng Feng,et al.  Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis. , 2006, Cancer research.

[37]  L. Fritschi,et al.  Validity of melanoma diagnosis in a community-based screening program. , 2006, American journal of epidemiology.

[38]  A. Marrari,et al.  Vaccination: role in metastatic melanoma , 2006, Expert review of anticancer therapy.

[39]  Allan Halpern,et al.  Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  P. Srivastava,et al.  A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients , 2006, Cancer Immunology, Immunotherapy.

[41]  J. Mordoh,et al.  A Phase I Study of an Allogeneic Cell Vaccine (VACCIMEL) With GM-CSF in Melanoma Patients , 2006, Journal of immunotherapy.

[42]  E. Warshaw,et al.  Diagnosing and managing cutaneous pigmented lesions: Primary care physicians versus dermatologists , 2006, Journal of General Internal Medicine.

[43]  W. Berdel,et al.  Proteasome inhibition in multiple myeloma. , 2006, European journal of cancer.

[44]  Alessandra Marini,et al.  Epigenetic silencing of the PTEN gene in melanoma. , 2006, Cancer research.

[45]  N. Bercovici,et al.  Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate , 2006, Cancer Immunology, Immunotherapy.

[46]  O. Perez,et al.  Immunological strategies to fight skin cancer. , 2006, Skin therapy letter.

[47]  R. MacKie,et al.  Value of sentinel node status as a prognostic factor in melanoma: prospective observational study , 2006, BMJ : British Medical Journal.

[48]  J. J. Coleman,et al.  The Prognostic Importance of Sentinel Lymph Node Biopsy in Thin Melanoma , 2006, Annals of Surgical Oncology.

[49]  A. Enk,et al.  Induction of strong and persistent MelanA/MART‐1‐specific immune responses by adjuvant dendritic cell‐based vaccination of stage II melanoma patients , 2006, International journal of cancer.

[50]  Tao Liu,et al.  Histone deacetylase inhibitors: multifunctional anticancer agents. , 2006, Cancer treatment reviews.

[51]  Stephen W Dusza,et al.  Level of Confidence in Diagnosis: Clinical Examination Versus Dermoscopy Examination , 2006, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[52]  M. Smylie,et al.  Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas , 2006, Journal of Neuro-Oncology.

[53]  S. Steinberg,et al.  Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma , 2006, Clinical Cancer Research.

[54]  D. Fisher,et al.  c-Met Expression Is Regulated by Mitf in the Melanocyte Lineage* , 2006, Journal of Biological Chemistry.

[55]  R. Hofmann-Wellenhof,et al.  Naevogenesis: new thoughts based on dermoscopy , 2006, The British journal of dermatology.

[56]  Arjun Chanmugam,et al.  Cutaneous malignant melanoma. , 2006, Mayo Clinic proceedings.

[57]  D. Elder.  Pathology of Melanoma , 2006, Clinical Cancer Research.

[58]  A. Lowy,et al.  Sentinel lymph node biopsy in thin melanoma patients , 2006, Journal of surgical oncology.

[59]  T. Wagner,et al.  Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. , 2006, International journal of oncology.

[60]  Tak W. Mak,et al.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.

[61]  T. Vogel,et al.  Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100 , 2006, Cancer.

[62]  D. Elder,et al.  Incomplete biopsy of melanocytic lesions can impair the accuracy of pathological diagnosis. , 2006, The Australasian journal of dermatology.

[63]  L. Mccauley,et al.  Rap1GAP inhibits tumor growth in oropharyngeal squamous cell carcinoma. , 2006, The American journal of pathology.

[64]  J. Aitken,et al.  Trends for in situ and Invasive Melanoma in Queensland, Australia, 1982–2002 , 2006, Cancer Causes & Control.

[65]  D. Coit,et al.  Results of Sentinel Lymph Node Biopsy in Patients With Thin Melanoma , 2006, Annals of Surgical Oncology.

[66]  J. Aitken,et al.  Clinical outcomes from skin screening clinics within a community-based melanoma screening program. , 2006, Journal of the American Academy of Dermatology.

[67]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[68]  M. Mihm,et al.  Prognosticators of melanoma, the melanoma report, and the sentinel lymph node , 2006, Modern Pathology.

[69]  Michael Heberer,et al.  Advanced Liposomal Vectors as Cancer Vaccines in Melanoma Immunotherapy , 2006, Journal of liposome research.

[70]  N. Hayward,et al.  Cutaneous melanoma susceptibility and progression genes. , 2005, Cancer letters.

[71]  A. Aguirre,et al.  Dendritic cell immunizations alone or combined with low doses of interleukin‐2 induce specific immune responses in melanoma patients , 2005, Clinical and experimental immunology.

[72]  Li Zhao,et al.  Oncogenic PI3K deregulates transcription and translation , 2005, Nature Reviews Cancer.

[73]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[74]  M. Herlyn,et al.  Targeting Intracellular Signaling Pathways as a Novel Strategy in Melanoma Therapeutics , 2005, Annals of the New York Academy of Sciences.

[75]  R. Dellavalle,et al.  Statins and fibrates for preventing melanoma. , 2005, The Cochrane database of systematic reviews.

[76]  C. Balch,et al.  Screening for cutaneous melanoma. , 2005, Surgical oncology clinics of North America.

[77]  V. Sondak,et al.  Sentinel node biopsy for thin melanomas: which patients should be considered? , 2005, Cancer control : journal of the Moffitt Cancer Center.

[78]  C. Garbe,et al.  Interventional study in 1,232 young German children to prevent the development of melanocytic nevi failed to change sun exposure and sun protective behavior , 2005, International journal of cancer.

[79]  A. Hauschild,et al.  Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes , 2005, Modern Pathology.

[80]  M. Berwick,et al.  Breslow depth of cutaneous melanoma: impact of factors related to surveillance of the skin, including prior skin biopsies and family history of melanoma. , 2005, Journal of the American Academy of Dermatology.

[81]  R. Turner,et al.  Melanoma recurrence patterns after negative sentinel lymphadenectomy. , 2005, Archives of surgery.

[82]  R. Marais,et al.  Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation , 2005, The Journal of cell biology.

[83]  Lisa M. Schwartz,et al.  Skin biopsy rates and incidence of melanoma: population based ecological study , 2005, BMJ : British Medical Journal.

[84]  L. Ben-Porat,et al.  Sun exposure and mortality from melanoma. , 2005, Journal of the National Cancer Institute.

[85]  M. Demierre,et al.  New treatments for melanoma. , 2005, Dermatology nursing.

[86]  E. Moran,et al.  Nomenclature of the ARID family of DNA-binding proteins. , 2005, Genomics.

[87]  B. Diffey,et al.  Sunscreens and melanoma: the future looks bright , 2005, The British journal of dermatology.

[88]  Jennifer L. Schwartz,et al.  Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. , 2005, Journal of the American College of Surgeons.

[89]  R. Scolyer,et al.  A Sentinel Node Biopsy Does Not Increase the Incidence of In-Transit Metastasis in Patients With Primary Cutaneous Melanoma , 2005, Annals of Surgical Oncology.

[90]  P. LoRusso,et al.  A phase II study of bortezomib in the treatment of metastatic malignant melanoma , 2005, Cancer.

[91]  B. Bett.  Large or multiple congenital melanocytic nevi: occurrence of cutaneous melanoma in 1008 persons. , 2005, Journal of the American Academy of Dermatology.

[92]  A. Enk,et al.  A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr) , 2005, Cancer Immunology, Immunotherapy.

[93]  M. Shehata,et al.  Rel/Nuclear factor-kappa B apoptosis pathways in human cervical cancer cells , 2005, Cancer Cell International.

[94]  H. Mukhtar,et al.  Anti‐proliferative and proapoptotic effects of (−)‐epigallocatechin‐3‐gallate on human melanoma: Possible implications for the chemoprevention of melanoma , 2005, International journal of cancer.

[95]  P. Khavari,et al.  Melanoma genetics and the development of rational therapeutics. , 2005, The Journal of clinical investigation.

[96]  M. Landthaler,et al.  Overexpression and hyperphosphorylation of retinoblastoma protein in the progression of malignant melanoma , 2005, Modern Pathology.

[97]  H. Kerl,et al.  Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. , 2005, Archives of dermatology.

[98]  M. Berwick,et al.  The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma , 2005, Journal of cutaneous pathology.

[99]  J. Grob,et al.  First prospective study of the recognition process of melanoma in dermatological practice. , 2005, Archives of dermatology.

[100]  Hani Doss,et al.  Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). , 2005, Oncology reports.

[101]  C. Lindsley,et al.  The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation. , 2005, Current topics in medicinal chemistry.

[102]  S. Chimenti,et al.  Imiquimod Treatment of Superficial and Nodular Basal Cell Carcinoma: 12‐Week Open‐Label Trial , 2005, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[103]  V. Sondak,et al.  Cutaneous melanoma: pathogenesis and rationale for chemoprevention. , 2005, Critical reviews in oncology/hematology.

[104]  L. Ben-Porat,et al.  Association of melanoma and neurocutaneous melanocytosis with large congenital melanocytic naevi—results from the NYU–LCMN registry , 2005, The British journal of dermatology.

[105]  M. Gonen,et al.  Characterization of Micrometastatic Disease in Melanoma Sentinel Lymph Nodes by Enhanced Pathology: Recommendations for Standardizing Pathologic Analysis , 2005, The American journal of surgical pathology.

[106]  M. Martinka,et al.  Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  L. Larue,et al.  Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression , 2005, Nature.

[108]  Dirk Strumberg,et al.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  L. Zon,et al.  BRAF Mutations Are Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma , 2005, Current Biology.

[110]  A. Marghoob,et al.  The association between large congenital melanocytic naevi and cutaneous melanoma: preliminary findings from an Internet-based registry of 379 patients , 2005, Melanoma research.

[111]  A. Viale,et al.  Distinction of desmoplastic melanoma from non-desmoplastic melanoma by gene expression profiling. , 2005, The Journal of investigative dermatology.

[112]  K. Nishioka,et al.  Genomic alterations in primary cutaneous melanomas detected by metaphase comparative genomic hybridization with laser capture or manual microdissection: 6p gains may predict poor outcome. , 2005, Cancer genetics and cytogenetics.

[113]  A. Kopf,et al.  Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. , 2004, JAMA.

[114]  R. DePinho,et al.  Impaired processing of DNA photoproducts and ultraviolet hypermutability with loss of p16INK4a or p19ARF. , 2004, Journal of the National Cancer Institute.

[115]  T. Golub,et al.  Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. , 2004, Cancer cell.

[116]  J. Hecht,et al.  Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  E. Bissonette,et al.  Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  D. Gomez,et al.  Active Specific Immunotherapy of Melanoma with a GM3 Ganglioside-Based Vaccine: A Report on Safety and Immunogenicity , 2004, Journal of immunotherapy.

[119]  E. Rowinsky.  Targeting the molecular target of rapamycin (mTOR) , 2004, Current opinion in oncology.

[120]  N. Dang,et al.  CD26/dipeptidyl peptidase IV and its role in cancer. , 2004, Histology and histopathology.

[121]  M. Cook.  Benign melanocytic lesions mimicking melanomas. , 2004, Pathology.

[122]  R. Scolyer,et al.  Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. , 2004, American journal of clinical pathology.

[123]  Geoffrey S Ginsburg,et al.  Targeted therapies for cancer 2004. , 2004, American journal of clinical pathology.

[124]  J. Cheng,et al.  Deregulated Akt3 Activity Promotes Development of Malignant Melanoma , 2004, Cancer Research.

[125]  Richard A Scolyer,et al.  Desmoplastic melanoma: a diagnostic trap for the unwary. , 2004, Pathology.

[126]  Claus Garbe,et al.  Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  Glenn Merlino,et al.  Ultraviolet B but not Ultraviolet A Radiation Initiates Melanoma , 2004, Cancer Research.

[128]  S. Chan,et al.  Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer , 2004, British Journal of Cancer.

[129]  Michael B Atkins,et al.  Management of cutaneous melanoma. , 2004, The New England journal of medicine.

[130]  N. Seeram,et al.  Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. , 2004, Anticancer research.

[131]  D. Morton,et al.  Contemporary surgical treatment of advanced-stage melanoma. , 2004, Archives of surgery.

[132]  V. Sondak,et al.  Melanoma margins: the importance and need for more evidence-based trials. , 2004, Archives of dermatology.

[133]  J. Wargo,et al.  Role of Dendritic Cell Phenotype, Determinant Spreading, and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy , 2004, Journal of immunotherapy.

[134]  E. Bissonette,et al.  Assessment of the Toxicities of Systemic Low-Dose Interleukin-2 Administered in Conjunction with a Melanoma Peptide Vaccine , 2004, Journal of immunotherapy.

[135]  K. Helin,et al.  E2F target genes: unraveling the biology. , 2004, Trends in biochemical sciences.

[136]  A. Ackerman,et al.  Sentinel node biopsy has no benefit for patients whose primary cutaneous melanoma has metastasized to a lymph node and therefore should be abandoned now , 2004, The British journal of dermatology.

[137]  J. Weber,et al.  Immune Responses to a Class II Helper Peptide Epitope in Patients with Stage III/IV Resected Melanoma , 2004, Clinical Cancer Research.

[138]  A. Cochran,et al.  The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma , 2004, The British journal of dermatology.

[139]  Kimi Yamakoshi,et al.  The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. , 2004, The journal of medical investigation : JMI.

[140]  Mark Shackleton,et al.  Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[141]  P. Chapman,et al.  Sequential Immunization of Melanoma Patients with GD3 Ganglioside Vaccine and Anti-Idiotypic Monoclonal Antibody That Mimics GD3 Ganglioside , 2004, Clinical Cancer Research.

[142]  K. Sparbier,et al.  Vaccination with hybrids of tumor and dendritic cells induces tumor‐specific T‐cell and clinical responses in melanoma stage III and IV patients , 2004, International journal of cancer.

[143]  M. Mareel,et al.  Melanoma cells secrete follistatin, an antagonist of activin-mediated growth inhibition , 2004, Oncogene.

[144]  M. Ross,et al.  Lessons learned from the Sunbelt Melanoma Trial , 2004, Journal of surgical oncology.

[145]  W. McCarthy.  The Australian experience in sun protection and screening for melanoma , 2004, Journal of surgical oncology.

[146]  R. Elashoff,et al.  Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node , 2004, Modern Pathology.

[147]  Richard A Scolyer,et al.  Pathology of melanocytic lesions: New, controversial, and clinically important issues , 2004, Journal of surgical oncology.

[148]  R. Scolyer,et al.  The history and future of melanoma staging , 2004, Journal of surgical oncology.

[149]  G. Zambruno,et al.  In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide , 2004, Melanoma research.

[150]  R. Götz,et al.  Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure , 2004, BMC Cancer.

[151]  P. V. van Diest,et al.  Sentinel lymph node investigation in melanoma: detailed analysis of the yield from step sectioning and immunohistochemistry , 2004, Journal of Clinical Pathology.

[152]  V. Sondak,et al.  Standard immunostains for melanoma in sentinel lymph node specimens: which ones are most useful? , 2004, Journal of the American Academy of Dermatology.

[153]  J. Trosko,et al.  Epigenetics and cancer: implications for drug discovery and safety assessment. , 2004, Toxicology and applied pharmacology.

[154]  Natale Cascinelli,et al.  An Evidence‐based Staging System for Cutaneous Melanoma 1 , 2004, CA: a cancer journal for clinicians.

[155]  J. Adams.  The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.

[156]  J. Becker,et al.  Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis , 2004, Journal of carcinogenesis.

[157]  J. Malvehy,et al.  Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate , 2004, Cancer Immunology, Immunotherapy.

[158]  Jeremy MG Taylor,et al.  Mitotic Rate and Younger Age Are Predictors of Sentinel Lymph Node Positivity: Lessons Learned From the Generation of a Probabilistic Model , 2004, Annals of Surgical Oncology.

[159]  J. Manola,et al.  A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma , 2004, Clinical Cancer Research.

[160]  M. van de Rijn,et al.  High-Resolution Array-Based Comparative Genomic Hybridization for Distinguishing Paraffin-Embedded Spitz Nevi and Melanomas , 2004, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[161]  A. Stromberg,et al.  Correlation Between Prognostic Factors and Increasing Age in Melanoma , 2004, Annals of Surgical Oncology.

[162]  M. Holick,et al.  Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. , 2004, The American journal of clinical nutrition.

[163]  J. Thomas,et al.  Excision margins in high-risk malignant melanoma. , 2004, The New England journal of medicine.

[164]  H Jick,et al.  Statin use and cancer risk in the General Practice Research Database , 2004, British Journal of Cancer.

[165]  A. Alavi,et al.  Mitotic Rate as a Predictor of Sentinel Lymph NodePositivity in Patients With Thin Melanomas , 2004, Annals of Surgical Oncology.

[166]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[167]  I. Weissman,et al.  Therapeutic implications of cancer stem cells. , 2004, Current opinion in genetics & development.

[168]  Jennifer L. Schwartz,et al.  Desmoplastic and neurotropic melanoma , 2004, Cancer.

[169]  S. Menzies,et al.  Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma , 2004, Cancer Immunology, Immunotherapy.

[170]  R. DePinho,et al.  The differential impact of p16INK4a or p19ARF deficiency on cell growth and tumorigenesis , 2004, Oncogene.

[171]  M. Mescher,et al.  Phase I Trial of Large Multivalent Immunogen Derived from Melanoma Lysates in Patients with Disseminated Melanoma , 2004, Clinical Cancer Research.

[172]  E. Calonje,et al.  Deep penetrating naevus: clinicopathological study of 31 cases with further delineation of histological features allowing distinction from other pigmented benign melanocytic lesions and melanoma , 2003, Histopathology.

[173]  W. Stolz,et al.  Identification of differentially expressed genes in models of melanoma progression by cDNA array analysis: SPARC, MIF and a novel cathepsin protease characterize aggressive phenotypes , 2003, Experimental dermatology.

[174]  Sing Kai Lo,et al.  Interobserver Reproducibility of Histopathologic Prognostic Variables in Primary Cutaneous Melanomas , 2003, The American journal of surgical pathology.

[175]  C. Garbe,et al.  Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. , 2003, The Lancet. Oncology.

[176]  V. Sondak,et al.  Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. , 2003, Seminars in cancer biology.

[177]  R. Kuwahara,et al.  Treatment of lentigo maligna with topical imiquimod , 2003, The British journal of dermatology.

[178]  M. Lebwohl,et al.  Isoflavone genistein: photoprotection and clinical implications in dermatology. , 2003, The Journal of nutrition.

[179]  J. Zitelli,et al.  The management of regional lymph nodes in cancer , 2003, The British journal of dermatology.

[180]  M. Walker,et al.  Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. , 2003, Surgery.

[181]  V. Sondak,et al.  Pros and cons of adjuvant interferon in the treatment of melanoma. , 2003, The oncologist.

[182]  P. Berg,et al.  Congenital melanocytic naevi and cutaneous melanoma , 2003, Melanoma research.

[183]  M. Tucker,et al.  Germline splicing mutations of CDKN2A predispose to melanoma , 2003, Oncogene.

[184]  R. Scolyer,et al.  Pathologic Review of Negative Sentinel Lymph Nodes in Melanoma Patients With Regional Recurrence: A Clinicopathologic Study of 1152 Patients Undergoing Sentinel Lymph Node Biopsy , 2003, The American journal of surgical pathology.

[185]  Steven A. Rosenberg,et al.  Adoptive-cell-transfer therapy for the treatment of patients with cancer , 2003, Nature Reviews Cancer.

[186]  S. Rosenberg,et al.  Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[187]  M. Mitchell.  Immunotherapy as part of combinations for the treatment of cancer. , 2003, International immunopharmacology.

[188]  E. Gillanders,et al.  Localization of a novel melanoma susceptibility locus to 1p22. , 2003, American journal of human genetics.

[189]  M. Gore,et al.  Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. , 2003, Cancer treatment reviews.

[190]  J. J. Coleman,et al.  Patterns of Initial Recurrence and Prognosis after Sentinel Lymph Node Biopsy and Selective Lymphadenectomy for Melanoma , 2003, Plastic and reconstructive surgery.

[191]  A. Eggermont,et al.  The development of optimal pathological assessment of sentinel lymph nodes for melanoma , 2003, The Journal of pathology.

[192]  S. Rosenberg,et al.  Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class II-Restricted Peptides from Melanoma-Associated Antigens , 2003, Journal of immunotherapy.

[193]  S. Itohara,et al.  Myeloproliferative stem cell disorders by deregulated Rap1 activation in SPA-1-deficient mice. , 2003, Cancer cell.

[194]  L. Thomas,et al.  Relevance of Vertical Growth Pattern in Thin Level II Cutaneous Superficial Spreading Melanomas , 2003, The American journal of surgical pathology.

[195]  S. Rosenberg,et al.  Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. , 2003, Human gene therapy.

[196]  B. Bastian.  Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer , 2003, Oncogene.

[197]  D. Gutmann,et al.  Role of the Rap1 GTPase in astrocyte growth regulation , 2003, Glia.

[198]  M. G. Fleming,et al.  Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. , 2003, Journal of the American Academy of Dermatology.

[199]  W. Alvord,et al.  Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[200]  D. Purdie,et al.  Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine , 2003, Cancer Immunology, Immunotherapy.

[201]  D. Morton,et al.  Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[202]  H. Gietema,et al.  Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[203]  Yuting Zhang,et al.  Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma , 2003, Cancer.

[204]  Glenn Merlino,et al.  Modeling gene-environment interactions in malignant melanoma. , 2003, Trends in molecular medicine.

[205]  R. Elashoff,et al.  Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[206]  M. Mita,et al.  The Molecular Target of Rapamycin (mTOR) as a Therapeutic Target Against Cancer , 2003, Cancer biology & therapy.

[207]  L. Ferreira,et al.  Vertical growth phase and positive sentinel node in thin melanoma. , 2003, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[208]  A. Redkar,et al.  Resveratrol is a potent inducer of apoptosis in human melanoma cells. , 2003, Cancer letters.

[209]  W. Sterry,et al.  Intradermal injection of Newcastle disease virus‐modified autologous melanoma cell lysate and interleukin‐2 for adjuvant treatment of melanoma patients with resectable stage III disease , 2003, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[210]  M. Pizzichetta,et al.  A Two-Year Regional Program for the Early Detection of Cutaneous Melanoma , 2003, Tumori.

[211]  C. Yen,et al.  Modelling the cost-effectiveness of sentinel lymph node mapping and adjuvant interferon treatment for stage II melanoma , 2002, Melanoma research.

[212]  M. Ross,et al.  Patterns of early recurrence after sentinel lymph node biopsy for melanoma. , 2002, American journal of surgery.

[213]  Jonathan J. Lewis,et al.  Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[214]  Hua Yu,et al.  Roles of activated Src and Stat3 signaling in melanoma tumor cell growth , 2002, Oncogene.

[215]  D. Pinkel,et al.  Genetic changes in neoplasms arising in congenital melanocytic nevi: differences between nodular proliferations and melanomas. , 2002, The American journal of pathology.

[216]  R. Elashoff,et al.  Prolonged Survival of Patients Receiving Active Immunotherapy With Canvaxin Therapeutic Polyvalent Vaccine After Complete Resection of Melanoma Metastatic to Regional Lymph Nodes , 2002, Annals of surgery.

[217]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[218]  M. Marberger,et al.  Prevention and screening , 2002 .

[219]  D. Mahvi,et al.  Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: report of a phase I/IB study. , 2002, Human gene therapy.

[220]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[221]  R. Czajkowski,et al.  Cell cycle in sporadic melanoma , 2002, International journal of dermatology.

[222]  M. Berwick,et al.  Quantifying the Change of Melanoma Incidence by Breslow Thickness , 2002, Biometrics.

[223]  Bruce Kupelnick,et al.  Use of topical sunscreens and the risk of malignant melanoma: a meta-analysis of 9067 patients from 11 case-control studies. , 2002, American journal of public health.

[224]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[225]  R. Eeles,et al.  Influence of cytokine gene polymorphisms on the development of prostate cancer. , 2002, Cancer research.

[226]  Jeffrey E Gershenwald,et al.  Targeting Lymphatic Metastasis , 2002, Science.

[227]  W. Hohenberger,et al.  Lymph node dissection for clinically evident lymph node metastases of malignant melanoma. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[228]  T. Peretz,et al.  Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV) , 2002, British Journal of Cancer.

[229]  D. Elder,et al.  Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. , 2002, Archives of dermatology.

[230]  E. Farmer.  The fundamental issue of diagnosis. , 2002, Archives of dermatology.

[231]  B. Bastian,et al.  Persistent (Recurrent) Spitz Nevi: A Histopathologic, Immunohistochemical, and Molecular Pathologic Study of 22 Cases , 2002, The American journal of surgical pathology.

[232]  V. Sondak,et al.  Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[233]  M. Lens,et al.  Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[234]  L. Naldi,et al.  The epidemiology of skin cancer , 2002, The British journal of dermatology.

[235]  H. van Steeg,et al.  Suppression of UV carcinogenesis by difluoromethylornithine in nucleotide excision repair-deficient Xpa knockout mice. , 2002, Cancer research.

[236]  H. Kittler,et al.  Diagnostic accuracy of dermoscopy. , 2002, The Lancet. Oncology.

[237]  A. Díaz,et al.  An Anti-Idiotype Vaccine Elicits a Specific Response to N-Glycolyl Sialic Acid Residues of Glycoconjugates in Melanoma Patients1 , 2002, The Journal of Immunology.

[238]  M. Ross,et al.  Reply to shaw and thompson: “Frequency of nonsentinel lymph node metastasis in melanoma” , 2002 .

[239]  J. Aitken,et al.  A randomised trial of population screening for melanoma , 2002, Journal of medical screening.

[240]  H. Brantjes,et al.  TCF: Lady Justice Casting the Final Verdict on the Outcome of Wnt Signalling , 2002, Biological chemistry.

[241]  E. Beale,et al.  Phosphoenolpyruvate carboxykinase is induced in growth-arrested hepatoma cells. , 2002, Biochemical and biophysical research communications.

[242]  J. Elwood.  Developing areas in cancer in New Zealand. , 2002, Japanese journal of clinical oncology.

[243]  Jongkyeong Chung,et al.  Akt: versatile mediator of cell survival and beyond. , 2002, Journal of biochemistry and molecular biology.

[244]  M. Herlyn,et al.  Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development , 2001, Oncogene.

[245]  R. Hofmann-Wellenhof,et al.  Dermoscopic classification of atypical melanocytic nevi (Clark nevi). , 2001, Archives of dermatology.

[246]  W. Stolz,et al.  Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II , 2001, Melanoma research.

[247]  V. Engelhard,et al.  Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[248]  L. Sandkuijl,et al.  Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. , 2001, American journal of human genetics.

[249]  N. Cascinelli,et al.  Impact of clinical trials on the treatment of melanoma. , 2001, Surgical oncology clinics of North America.

[250]  D. Duffy,et al.  MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. , 2001, American journal of human genetics.

[251]  J. Thompson,et al.  Lymph-node metastases in patients with melanoma: what is the optimum management? , 2001, The Lancet. Oncology.

[252]  D. Carrasco,et al.  Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis , 2001, Nature.

[253]  A. Berns,et al.  Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice , 2001, Nature.

[254]  D. Roberts,et al.  Malignant melanoma in South Wales: changing trends in presentation (1986–98) , 2001, Clinical and experimental dermatology.

[255]  S. Moss,et al.  The relation between mortality from malignant melanoma and early detection in the Cancer Research Campaign Mole Watcher Study , 2001, British Journal of Cancer.

[256]  R. Steinman,et al.  Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. , 2001, Cancer research.

[257]  N Cascinelli,et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[258]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[259]  V. Hearing,et al.  Involvement of ITF2 in the Transcriptional Regulation of Melanogenic Genes* , 2001, The Journal of Biological Chemistry.

[260]  F. Marincola,et al.  Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma , 2001, Journal of immunotherapy.

[261]  S. Stratton.  Prevention of non-melanoma skin cancer , 2001, Current oncology reports.

[262]  N. Gruis,et al.  Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma. , 2001, Cancer research.

[263]  C. Brunia,et al.  Wait and see. , 2001, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[264]  P. V. van Diest,et al.  The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma , 2001, Cancer.

[265]  H. Welch.  Informed choice in cancer screening. , 2001, JAMA.

[266]  M. Ross,et al.  Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[267]  H. Kerl,et al.  Tutorial on melanocytic lesions. , 2001, The American Journal of dermatopathology.

[268]  A. D. Dei Tos,et al.  Morphological Analysis of Nevoid Melanoma: A Study of 20 Cases With A Review of the Literature , 2001, The American Journal of dermatopathology.

[269]  V. Sondak,et al.  High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[270]  K. Namboodiri,et al.  Inverse association of non-steroidal anti-inflammatory drugs and malignant melanoma among women. , 2001, Oncology reports.

[271]  D. Reintgen,et al.  Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. , 2001, Journal of the American Academy of Dermatology.

[272]  R. Foster,et al.  Giant Congenital Melanocytic Nevi: The Significance of Neurocutaneous Melanosis in Neurologically Asymptomatic Children , 2001, Plastic and reconstructive surgery.

[273]  A. Hart,et al.  The Value of Cloquet’s Node in Predicting Melanoma Nodal Metastases in the Pelvic Lymph Node Basin , 2001, Annals of Surgical Oncology.

[274]  M. Helfand,et al.  Screening for skin cancer. , 2001, American journal of preventive medicine.

[275]  P. Pollock,et al.  Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. , 2001, Cancer research.

[276]  M. Gadd,et al.  Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study , 2001, Melanoma research.

[277]  P. Allen,et al.  S100 expression in cutaneous scars: a potential diagnostic pitfall in the diagnosis of desmoplastic melanoma , 2001, Histopathology.

[278]  A. Sober,et al.  Melastatin expression and prognosis in cutaneous malignant melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[279]  B. Coldiron.  Sentinel node biopsy: who needs it? , 2000, International journal of dermatology.

[280]  R. Marks,et al.  Epidemiology of melanoma , 2000, Clinical and experimental dermatology.

[281]  D. Troxel,et al.  Diagnostic Errors in Surgical Pathology Uncovered by a Review of Malpractice Claims , 2000, International journal of surgical pathology.

[282]  A. Marghoob,et al.  Large Congenital Melanocytic Nevi and the Risk for Development of Malignant Melanoma and Neurocutaneous Melanocytosis , 2000, Pediatrics.

[283]  C. Garbe,et al.  Time trends of cutaneous melanoma in Queensland, Australia and Central Europe , 2000, Cancer.

[284]  M. Weinstock.  Early detection of melanoma. , 2000, JAMA.

[285]  N. Sampas,et al.  Molecular classification of cutaneous malignant melanoma by gene expression profiling , 2000, Nature.

[286]  U. Ringborg,et al.  Trends in mortality from malignant melanoma in Sweden, 1970–1996 , 2000, Cancer.

[287]  A. Halpern,et al.  Patterns of detection in patients with cutaneous melanoma , 2000, Cancer.

[288]  J. J. Coleman,et al.  Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma , 2000, Cancer.

[289]  C. Goding.  Melanocyte development and malignant melanoma. , 2000, Forum.

[290]  C. Sigman,et al.  Retinoids in chemoprevention and differentiation therapy. , 2000, Carcinogenesis.

[291]  F. Marincola,et al.  Phase 1 Study in Patients With Metastatic Melanoma of Immunization With Dendritic Cells Presenting Epitopes Derived From the Melanoma-Associated Antigens MART-1 and gp100 , 2000, Journal of immunotherapy.

[292]  R. Burton.  Malignant melanoma in the year 2000 , 2000, CA: a cancer journal for clinicians.

[293]  A. Testori,et al.  Sentinel Lymph Node Biopsy in Cutaneous Melanoma: The WHO Melanoma Program Experience , 2000, Annals of Surgical Oncology.

[294]  L. Sobin,et al.  World Health Organization classification of tumors , 2000, Cancer.

[295]  Tim K. Lee,et al.  Broad-spectrum sunscreen use and the development of new nevi in white children: A randomized controlled trial. , 2000, JAMA.

[296]  V. Sondak,et al.  High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[297]  B. Dréno,et al.  Delays in diagnosis and melanoma prognosis (II): The role of doctors , 2000, International journal of cancer.

[298]  M. Lowes,et al.  Benign melanocytic proliferative nodule within a congenital naevus , 2000, The Australasian journal of dermatology.

[299]  D. Bishop,et al.  Mutation screening of the CDKN2A promoter in melanoma families , 2000, Genes, chromosomes & cancer.

[300]  S. Moss,et al.  Feasibility of targeted early detection for melanoma: a population-based screening study , 2000, British Journal of Cancer.

[301]  T. Godfrey,et al.  Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. , 2000, Cancer research.

[302]  P. Schrier,et al.  Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. , 2000, Human gene therapy.

[303]  C. Musselli,et al.  Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3‐lactone‐KLH conjugate plus immunological adjuvant QS‐21 , 2000, International journal of cancer.

[304]  D. Schadendorf,et al.  Phase 2 Trial of Vaccination With Tyrosinase Peptides and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma , 2000, Journal of immunotherapy.

[305]  A. Enk,et al.  Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.

[306]  W. Stolz,et al.  Deficiency of a novel retinoblastoma binding protein 2-homolog is a consistent feature of sporadic human melanoma skin cancer. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[307]  K. Freedberg,et al.  Screening for malignant melanoma: A cost-effectiveness analysis. , 1999, Journal of the American Academy of Dermatology.

[308]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[309]  D L Morton,et al.  Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. , 1999, Annals of surgery.

[310]  Ames,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[311]  J. McCubrey,et al.  Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs , 1999, Leukemia.

[312]  G. Noël,et al.  [Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomized trial]. , 1999, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[313]  R. Gallagher,et al.  Follow-up and evaluation of skin cancer screening in British Columbia. , 1999, Journal of the American Academy of Dermatology.

[314]  D. Reintgen,et al.  Cost analysis of sentinel lymph node biopsy as an alternative to elective lymph node dissection in patients with malignant melanoma. , 1999, Surgical oncology clinics of North America.

[315]  S. Meier-Ewert,et al.  A Novel Gene (PLU-1) Containing Highly Conserved Putative DNA/Chromatin Binding Motifs Is Specifically Up-regulated in Breast Cancer* , 1999, The Journal of Biological Chemistry.

[316]  R. Rees,et al.  Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. , 1999, Human gene therapy.

[317]  A. Dabrowska,et al.  Lovastatin and tumor necrosis factor‐α exhibit potentiated antitumor effects against Ha‐ras‐transformed murine tumor Via inhibition of tumor‐induced angiogenesis , 1999, International journal of cancer.

[318]  M. Mihm,et al.  Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. , 1999, Human pathology.

[319]  D. H. Randle,et al.  Tumor spectrum in ARF-deficient mice. , 1999, Cancer research.

[320]  K. Busam.  Metastatic melanoma to the skin simulating blue nevus. , 1999, The American journal of surgical pathology.

[321]  M. Ross,et al.  Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[322]  S. Leong,et al.  Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. , 1999, Journal of immunotherapy.

[323]  D. Morton,et al.  Cytoreductive surgery and adjuvant immunotherapy: A new management paradigm for metastatic melanoma , 1999, CA: a cancer journal for clinicians.

[324]  S. Signoretti,et al.  Melanocytic nevi of palms and soles: a histological study according to the plane of section. , 1999, The American journal of surgical pathology.

[325]  F. Marincola,et al.  Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. , 1998, Journal of the National Cancer Institute.

[326]  M. Cattaruzza,et al.  Sunscreen use, wearing clothes, and number of nevi in 6- to 7-year-old European children. European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. , 1998, Journal of the National Cancer Institute.

[327]  D. Margolis,et al.  Validation of a melanoma prognostic model. , 1998, Archives of dermatology.

[328]  M. Mihm,et al.  Recommendations for the Reporting of Tissues Removed as Part of the Surgical Treatment of Cutaneous Melanoma , 1998 .

[329]  S. Jee,et al.  Curcumin induces a p53-dependent apoptosis in human basal cell carcinoma cells. , 1998, The Journal of investigative dermatology.

[330]  L. Thomas,et al.  Semiological Value of ABCDE Criteria in the Diagnosis of Cutaneous Pigmented Tumors , 1998, Dermatology.

[331]  F. Zindy,et al.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[332]  F. Haluska,et al.  Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines , 1998, Oncogene.

[333]  F. Ribeiro-Neto,et al.  Mitogenic and oncogenic properties of the small G protein Rap1b. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[334]  Jeffrey E. Lee,et al.  Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma , 1998, Annals of Surgical Oncology.

[335]  N. Barth,et al.  Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma. , 1998, Cancer biotherapy & radiopharmaceuticals.

[336]  M. Ross,et al.  Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[337]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[338]  S. Evans,et al.  Isolation of the Aspergillus nidulans sudD gene and its human homologue. , 1998, Gene.

[339]  C. Balch,et al.  Factors affecting survival following local, regional, or distant recurrence from localized melanoma , 1998, Journal of surgical oncology.

[340]  N. Cascinelli,et al.  Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial , 1998, The Lancet.

[341]  D. Reintgen,et al.  Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes , 1998, Annals of Surgical Oncology.

[342]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[343]  M. Ross,et al.  Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[344]  D. Stoppa-Lyonnet,et al.  Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. , 1998, Human molecular genetics.

[345]  D. Alberts,et al.  Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[346]  H Nagahara,et al.  Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[347]  P. Guldberg,et al.  Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. , 1997, Cancer research.

[348]  K. Bland,et al.  Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial. , 1997, Annals of surgery.

[349]  P. Limtrakul,et al.  Inhibitory effect of dietary curcumin on skin carcinogenesis in mice. , 1997, Cancer letters.

[350]  W. Hauck,et al.  Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[351]  Sibylle Mittnacht,et al.  Differential Phosphorylation of the Retinoblastoma Protein by G1/S Cyclin-dependent Kinases* , 1997, The Journal of Biological Chemistry.

[352]  S. Groshen,et al.  Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[353]  M. Mihm,et al.  Pathology of malignant melanoma. , 1996, The Surgical clinics of North America.

[354]  J. Bartek,et al.  The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. , 1996, Cancer research.

[355]  M. Kitagawa,et al.  The consensus motif for phosphorylation by cyclin D1‐Cdk4 is different from that for phosphorylation by cyclin A/E‐Cdk2. , 1996, The EMBO journal.

[356]  C. Garbe,et al.  Increase of melanocytic nevus counts in children during 5 years of follow-up and analysis of associated factors. , 1996, Archives of dermatology.

[357]  K. Ang,et al.  Radiation therapy for malignant melanoma. , 1996, The Surgical clinics of North America.

[358]  E. Petricoin,et al.  Laser Capture Microdissection , 1996, Science.

[359]  S. Menzies,et al.  Frequency and morphologic characteristics of invasive melanomas lacking specific surface microscopic features. , 1996, Archives of dermatology.

[360]  P. Meltzer,et al.  Twelve amplified and expressed genes localized in a single domain in glioma , 1996, Human Genetics.

[361]  A. Halpern,et al.  A Prognostic Model for Predicting 10-Year Survival in Patients with Primary Melanoma , 1996, Annals of Internal Medicine.

[362]  M. Mihm,et al.  Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. , 1996, Annals of surgery.

[363]  R. Swerlick,et al.  The melanoma epidemic : Is increased surveillance the solution or the problem ? , 1996 .

[364]  G. Giles,et al.  Has mortality from melanoma stopped rising in Australia? Analysis of trends between 1931 and 1994 , 1996, BMJ.

[365]  L. Chin,et al.  Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.

[366]  R W Sanson-Fisher,et al.  Screening for Melanoma by Primary Health Care Physicians: A Cost—Effectiveness Analysis , 1996, Journal of medical screening.

[367]  C. Begg,et al.  Screening for cutaneous melanoma by skin self-examination. , 1996, Journal of the National Cancer Institute.

[368]  D. Mehregan,et al.  Proliferating cell nuclear antigen staining in deep-penetrating nevi. , 1995, Journal of the American Academy of Dermatology.

[369]  C. O'brien,et al.  Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes , 1995, Melanoma research.

[370]  R. Spasoff.  Healing Medicare: Managing Health System Change the Canadian Way , 1995 .

[371]  H. Oettgen,et al.  GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. , 1995, Cancer research.

[372]  H. Haupt,et al.  Pagetoid melanocytosis. Histologic features in benign and malignant lesions. , 1995, The American journal of surgical pathology.

[373]  O. Gefeller,et al.  Melanoma and use of sunscreens: An EORTC case‐control study in germany, belgium and france , 1995 .

[374]  G. Hortobagyi,et al.  Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer , 1995, Cancer Chemotherapy and Pharmacology.

[375]  A. Swerdlow,et al.  The risk of melanoma in patients with congenital nevi: a cohort study. , 1995, Journal of the American Academy of Dermatology.

[376]  F. Lacroute,et al.  Inactivation of SSM4, a new Saccharomyces cerevisiae gene, suppresses mRNA instability due to rna14 mutations , 1994, Molecular and General Genetics MGG.

[377]  W. Clark,et al.  Germline p16 mutations in familial melanoma , 1994, Nature Genetics.

[378]  S. Rosenberg,et al.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.

[379]  D. Driscoll,et al.  Groin dissection in malignant melanoma , 1994, Annals of Surgical Oncology.

[380]  J. Austoker,et al.  Cancer Prevention in Primary Care: Melanoma: prevention and early diagnosis , 1994, BMJ.

[381]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[382]  W. Stolz,et al.  The ABCD rule of dermatoscopy. High prospective value in the diagnosis of doubtful melanocytic skin lesions. , 1994, Journal of the American Academy of Dermatology.

[383]  T. K. Das Gupta,et al.  Melanoma recurrence in a previously dissected lymph node basin. , 1994, Archives of surgery.

[384]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[385]  S. Vijayasaradhi,et al.  A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase , 1993, The Journal of experimental medicine.

[386]  K Wolff,et al.  In vivo epiluminescence microscopy: improvement of early diagnosis of melanoma. , 1993, The Journal of investigative dermatology.

[387]  C. Balch,et al.  Operative morbidity and risk factor assessment in melanoma patients undergoing inguinal lymph node dissection. , 1992, American journal of surgery.

[388]  K. Kraemer,et al.  Chemoprevention of Skin Cancer in Xeroderma Pigmentosum , 1992, The Journal of dermatology.

[389]  J. Kirkwood,et al.  Homozygous deletions within human chromosome band 9p21 in melanoma. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[390]  R. Elashoff,et al.  Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine , 1992, Annals of surgery.

[391]  E. R. Farmer,et al.  NIH Consensus conference. Diagnosis and treatment of early melanoma. , 1992, JAMA.

[392]  M. Citron,et al.  Pyrimidine dimer removal enhanced by DNA repair liposomes reduces the incidence of UV skin cancer in mice. , 1992, Cancer research.

[393]  P. Cooper.  Deep penetrating (plexiform spindle cell) nevus , 1992, Journal of cutaneous pathology.

[394]  D L Morton,et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.

[395]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[396]  R J Reed,et al.  Histologic Classification of the Combined Nevus: Analysis of the Variable Expression of Melanocytic Nevi , 1991, The American journal of surgical pathology.

[397]  R. Elashoff,et al.  Improved Long-term Survival After Lymphadenectomy of Melanoma Metastatic to Regional Nodes , 1991 .

[398]  R. Agarwal,et al.  Protection against ultraviolet B radiation-induced photocarcinogenesis in hairless mice by green tea polyphenols. , 1991, Carcinogenesis.

[399]  G. Halliday,et al.  Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. , 1991, The Journal of investigative dermatology.

[400]  Pearl S Huang,et al.  Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product , 1991, Nature.

[401]  D. Roses,et al.  Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine. , 1991, Cancer research.

[402]  D. Elder,et al.  Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. , 1991, Human pathology.

[403]  L. Requena,et al.  Pigmented spindle cell naevus , 1990, The British journal of dermatology.

[404]  K. Cornetta,et al.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. , 1990, The New England journal of medicine.

[405]  A. Halpern,et al.  Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. , 1990, Journal of the American Academy of Dermatology.

[406]  D. Shaw,et al.  The initial effects on workload and outcome of a public education campaign on early diagnosis and treatment of malignant melanoma in Leicestershire , 1990, The British journal of dermatology.

[407]  A. Halpern,et al.  Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.

[408]  J. Elwood,et al.  Effects of a health education campaign for the earlier diagnosis of melanoma. , 1989, British Journal of Cancer.

[409]  R. MacKie,et al.  PERSONAL RISK-FACTOR CHART FOR CUTANEOUS MELANOMA , 1989, The Lancet.

[410]  D. Housman,et al.  Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[411]  P. Green,et al.  Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. , 1989, The New England journal of medicine.

[412]  M. Everett.  Histopathology of Congenital Pigmented Nevi , 1989, The American Journal of dermatopathology.

[413]  E. B. Helwig,et al.  Deep Penetrating Nevus , 1989, The American journal of surgical pathology.

[414]  T. K. Das Gupta,et al.  Thin malignant melanomas with regression and metastases. , 1987, Archives of dermatology.

[415]  B. Nickoloff,et al.  Immunohistologic patterns of congenital nevocellular nevi. , 1986, Archives of dermatology.

[416]  F. Sim,et al.  Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. , 1986, Mayo Clinic proceedings.

[417]  M. Lebwohl,et al.  Importance of complete cutaneous examination for the detection of malignant melanoma. , 1986, Journal of the American Academy of Dermatology.

[418]  R. F. Ryan,et al.  Cutaneous melanoma : clinical management and treatment results worldwide , 1986 .

[419]  M. S. Blois,et al.  Thin level IV malignant melanoma. A subset in which level is the major prognostic indicator. , 1985, Annals of surgery.

[420]  A. Kopf,et al.  Early detection of malignant melanoma: The role of physician examination and self‐examination of the skin , 1985, CA: a cancer journal for clinicians.

[421]  M. N. Epstein,et al.  A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. , 1984, Human pathology.

[422]  S. Hurwitz,et al.  Patterns of congenital nevocellular nevi. A histologic study of thirty-eight cases. , 1983, Journal of the American Academy of Dermatology.

[423]  S. Hurwitz,et al.  Congenital nevocellular nevus: a review of the treatment controversy and a report of 46 cases. , 1983, Plastic and reconstructive surgery.

[424]  A. Kopf,et al.  Regression in malignant melanoma. , 1983, Journal of the American Academy of Dermatology.

[425]  S. Miller,et al.  Acral lentiginous melanoma in situ. , 1982, Plastic and reconstructive surgery.

[426]  A. Ackerman,et al.  A critique of techniques for biopsy of clinically suspected malignant melanomas , 1982, The American Journal of dermatopathology.

[427]  P. Duvillard,et al.  Malignant melanoma of the skin: Prognostic factors derived from a multifactorial analysis of 239 cases , 1982, The American Journal of dermatopathology.

[428]  N. Cascinelli,et al.  Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities , 1982, Cancer.

[429]  J. Melski,et al.  Small congenital nevocellular nevi and the risk of cutaneous melanoma. , 1982, The Journal of pediatrics.

[430]  E. Castilla,et al.  Epidemiology of congenital pigmented naevi: , 1981, The British journal of dermatology.

[431]  M. Hendrickson,et al.  Neoplasms arising in congenital giant nevi: Morphologic study of seven cases and a review of the literature , 1981, The American journal of surgical pathology.

[432]  E. B. Helwig,et al.  Melanocytic nevi in neonates. , 1981, Journal of the American Academy of Dermatology.

[433]  C. Balch,et al.  The prognostic significance of ulceration of cutaneous melanoma , 1980, Cancer.

[434]  A. Cox,et al.  Pigmented lesions in newborn infants , 1976, The British journal of dermatology.

[435]  M. Sporn,et al.  Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). , 1976, Federation proceedings.

[436]  E. Kaplan,et al.  The risk of malignancy in large congenital nevi. , 1974, Plastic and reconstructive surgery.

[437]  A Breslow,et al.  Thickness, Cross‐Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma , 1970, Annals of surgery.

[438]  W. Clark,et al.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin. , 1969, Cancer research.

[439]  A. Cochran.  Histology and prognosis in malignant melanoma , 1969, The Journal of pathology.

[440]  G. Pack,et al.  On the antiquity of melanoma , 1966, Cancer.

[441]  P. Greeley,et al.  INCIDENCE OF MALIGNANCY IN GIANT PIGMENTED NEVI , 1965, Plastic and reconstructive surgery.

[442]  M. Pers,et al.  Naevus Pigmentosus Giganticus , 1963 .

[443]  C. Morgan.  Observations ON CANCER: ITS PATHOLOGY, AND ITS RELATIONS TO THE ORGANISM AND TO OTHER MORBID GROWTHS , 1874 .

[444]  W. Norris.  Case of Fungoid Disease , 1820, Edinburgh medical and surgical journal.

[445]  H. Koh,et al.  Melanoma screening: focusing the public health journey. , 2007, Archives of dermatology.

[446]  P. Twomey.  Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-1, an international multicenter trial. , 2007, Annals of surgery.

[447]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[448]  V. Sondak,et al.  The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma , 2007, Cancer.

[449]  C Michael White,et al.  Statins and Cancer Risk: A Meta-analysis , 2007 .

[450]  Alan Geller,et al.  Visual screening for malignant melanoma: a cost-effectiveness analysis. , 2007, Archives of dermatology.

[451]  D. Ren,et al.  Cutaneous head and neck melanoma treated with Mohs micrographic surgery. , 2005, Journal of the American Academy of Dermatology.

[452]  J. Barrett,et al.  The effect of sun exposure in determining nevus density in UK adolescent twins. , 2005, The Journal of investigative dermatology.

[453]  R. Marais,et al.  The role of B-RAF in melanoma , 2005, Cancer and Metastasis Reviews.

[454]  C. Pethiyagoda,et al.  Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells , 2004, Clinical & Experimental Metastasis.

[455]  N. Chattopadhyay,et al.  Transforming growth factor beta receptor family ligands inhibit hepatocyte growth factor synthesis and secretion from astrocytoma cells. , 2004, Brain research. Molecular brain research.

[456]  D. English,et al.  Prevention of Skin Cancer , 2004, Cancer Prevention — Cancer Causes.

[457]  Jennifer L. Schwartz,et al.  Staging workup, sentinel node biopsy, and follow-up tests for melanoma: update of current concepts. , 2004, Archives of dermatology.

[458]  M. Göttlicher.  Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. , 2004, Annals of hematology.

[459]  M. Jefford,et al.  The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. , 2004, Cancer immunity.

[460]  P. Carli,et al.  Clinical and Laboratory Investigations Improvement of malignant ⁄benign ratio in excised melanocytic lesions in the dermoscopy era : a retrospective study , 2004 .

[461]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[462]  D. Gutmann,et al.  Rap1 activity is elevated in malignant astrocytomas independent of tuberous sclerosis complex-2 gene expression. , 2003, International journal of oncology.

[463]  R. Lyles,et al.  Sentinel Lymph Node Mapping for Thick (≥4-mm) Melanoma: Should We Be Doing It? , 2003, Annals of Surgical Oncology.

[464]  D. Coit,et al.  Sentinel Lymph Node Biopsy for Patients With Cutaneous Desmoplastic Melanoma , 2003, Annals of Surgical Oncology.

[465]  N. Konishi,et al.  Operative Morbidity Associated with Groin Dissections , 2003, Surgery Today.

[466]  W. Seeger,et al.  cDNA array hybridization after laser-assisted microdissection from nonneoplastic tissue. , 2002, The American journal of pathology.

[467]  M. Gail,et al.  The promise and peril of surrogate end points in cancer research , 2002, Nature Reviews Cancer.

[468]  H. Ris,et al.  Morbidity and outcome after sentinel lymph node dissection in patients with early-stage malignant cutaneous melanoma. , 2002, Swiss surgery = Schweizer Chirurgie = Chirurgie suisse = Chirurgia svizzera.

[469]  B. Bastian.  Molecular cytogenetics as a diagnostic tool for typing melanocytic tumors. , 2002, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[470]  C. Denkert,et al.  Expression of cyclooxygenase 2 in human malignant melanoma. , 2001, Cancer research.

[471]  Robert L. Lawrence,et al.  Extending Medicare Coverage for Preventive and Other Services , 2000 .

[472]  A. Alavi,et al.  Incidence of Sentinel Node Metastasis in Patients With Thin Primary Melanoma (#1 mm) With Vertical Growth Phase , 2000, Annals of Surgical Oncology.

[473]  Jeffrey E. Lee,et al.  Role for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Thick (≥4 mm) Primary Melanoma , 2000, Annals of Surgical Oncology.

[474]  Eric S. Lander.  Array of hope , 1999, Nature Genetics.

[475]  T. Ulbright,et al.  The Pathologist's Perspective , 1999 .

[476]  David Hogg,et al.  Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma , 1999, Nature Genetics.

[477]  W. Kaelin.  Recent insights into the functions of the retinoblastoma susceptibility gene product. , 1997, Cancer investigation.

[478]  Y Taya,et al.  RB kinases and RB-binding proteins: new points of view. , 1997, Trends in biochemical sciences.

[479]  C W Cruse,et al.  Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. , 1996, Annals of surgery.

[480]  N. Hayward,et al.  Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma , 1996, Nature Genetics.

[481]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[482]  Y. Barenholz,et al.  Allogeneic human liposomal melanoma vaccine with or without IL-2 in metastatic melanoma patients: clinical and immunobiological effects. , 1995, Cancer biotherapy.

[483]  J. Melia,et al.  Early detection of cutaneous malignant melanoma in Britain. , 1995, International journal of epidemiology.

[484]  Barrett Rj.  The many faces of completely regressed malignant melanoma. , 1994 .

[485]  D. Reintgen,et al.  Recurrent malignant melanoma: the identification of prognostic factors to predict survival. , 1992, Annals of plastic surgery.

[486]  Rinus Plasmeijer,et al.  The Beauty and the Beast , 1992 .

[487]  A. Conney,et al.  Inhibitory effect of curcumin and some related dietary compounds on tumor promotion and arachidonic acid metabolism in mouse skin. , 1991, Advances in enzyme regulation.

[488]  C. Balch.  The role of elective lymph node dissection in melanoma: rationale, results, and controversies. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[489]  D. Roses.  Biopsy technique for suspected melanoma , 1985 .

[490]  B. Konz.  Congenital Nevocellular Nevi , 1984 .

[491]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[492]  M. Lorentzen,et al.  The incidence of malignant transformation in giant pigmented nevi. , 1977, Scandinavian journal of plastic and reconstructive surgery.